Hou, Jinlin Gane, Edward Balabanska, Rozalina Zhang, Wenhong Zhang, Jiming Lim, Tien Huey Xie, Qing Yeh, Chau-Ting Yang, Sheng-Shun Liang, Xieer
...
Published in
Clinical and molecular hepatology
Four-week treatment of linvencorvir (RO7049389) was generally safe and well tolerated, and showed anti-viral activity in chronic hepatitis B (CHB) patients. This study evaluated the efficacy, safety, and pharmacokinetics of 48-week treatment with linvencorvir plus standard of care (SoC) in CHB patients. This was a multicentre, non-randomized, non-c...
Xie, Li Chen, Hui Zhang, Li Ma, Yue Zhou, Yuan Yang, Yong-Yu Liu, Chang Wang, Yu-Li Yan, Ya-Jun Ding, Jia
...
Published in
Clinical and molecular hepatology
Cholestatic liver diseases including primary biliary cholangitis (PBC) are associated with active hepatic fibrogenesis, which ultimately progresses to cirrhosis. Activated hepatic stellate cells (HSCs) are the main fibrogenic effectors in response to cholangiocyte damage. JCAD regulates cell proliferation and malignant transformation in nonalcoholi...
Shan, Shan Zhao, Xinyan Jia, Jidong
Published in
Clinical and molecular hepatology
Hepatitis B virus (HBV) infection was highly endemic in China, where the prevalence of HBsAg was 9.7% in 1992. Comprehensive strategies, including universal infant hepatitis B vaccination with emphasis on timely birth-dose and 3-dose coverage, dramatically reduced the mother-to-infant transmission and early childhood acquisition of HBV, resulting i...
Liaw, Yun-Fan
Published in
Clinical and molecular hepatology
Sankar, Kamya Gong, Jun Osipov, Arsen Miles, Steven A Kosari, Kambiz Nissen, Nicholas N Hendifar, Andrew E Koltsova, Ekaterina K Yang, Ju Dong
Published in
Clinical and molecular hepatology
Liver cancer remains a challenge of global health, being the 4th leading cause of cancer death worldwide. Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer, and is usually precipitated by chronic viral infections (hepatitis B and C), non-alcoholic steatohepatitis, heavy alcohol use, and other factors which may lead to c...
Shi, Yingzhou Dong, Hang Sun, Shiwei Wu, Xiaoqin Fang, Jiansong Zhao, Jianbo Han, Junming Li, Zongyue Wu, Huixiao Liu, Luna
...
Published in
Clinical and molecular hepatology
To evaluate the causal correlation between complement components and non-viral liver diseases and their potential use as druggable targets. We conducted Mendelian randomization (MR) to assess the causal role of circulating complements in the risk of non-viral liver diseases. A complement-centric protein interaction network was constructed to explor...
Yeh, Ming-Lun Yu, Ming-Lung
Published in
Clinical and molecular hepatology
Yoon, Eileen L Jun, Dae Won
Published in
Clinical and molecular hepatology
Jung, Chan-Young Chang, Jai Won
Published in
Clinical and molecular hepatology
Hepatorenal syndrome (HRS), a progressive but potentially reversible deterioration of kidney function, remains a major complication in patients with advanced cirrhosis, often leading to death before liver transplantation (LT). Recent updates in the pathophysiology, definition, and classification of HRS have led to a complete revision of the nomencl...
Hsu, Yao-Chun Tseng, Cheng-Hao Kao, Jia-Horng
Published in
Clinical and molecular hepatology
Nucleos(t)ide analogues (NA) are widely used to treat hepatitis B virus (HBV) infection, but they cannot eradicate the virus and treatment duration can be lifelong if the endpoint is set at seroclearance of the hepatitis B surface antigen (HBsAg). As an alternative strategy, finite NA therapy without the prerequisite of HBsAg seroclearance has been...
